Literature DB >> 9171224

The construction and evaluation of SIV/HIV chimeras that express the envelope of European HIV type 1 isolates.

S Ranjbar1, S Jones, E J Stott, N Almond.   

Abstract

The molecular construction of SIV/HIV-1 chimeric viruses (or SHIVs), provides a means of infecting macaques with immunodeficiency viruses that express the envelope protein of HIV-1. However, to date, most SHIVs produced express the envelope of isolates of HIV-1 that have been passaged repeatedly in T cell lines. We have taken SHIV-4 and replaced an NheI-AvrII fragment that encompasses the gp120 region and the extracellular portion of gp41 with the equivalent region of two European isolates of HIV-1 (ACH320.3.1 and HIV-1Han-2). Neither of these viruses had been passaged in T cell lines for prolonged periods prior to molecular cloning. Virus stocks were prepared of both SHIV constructs. In vitro, the relative ability of each clone to replicate in four T cell lines mirrored closely the pattern observed with the parental virus donating the envelope sequences. In vivo, only one of the chimeric viruses was infectious in cynomolgus macaques and its recovery was transient. The factors that affect the replication of SHIVs in vitro and in vivo are discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9171224     DOI: 10.1089/aid.1997.13.797

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  6 in total

1.  Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

Authors:  J R Mascola; M G Lewis; G Stiegler; D Harris; T C VanCott; D Hayes; M K Louder; C R Brown; C V Sapan; S S Frankel; Y Lu; M L Robb; H Katinger; D L Birx
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.

Authors:  P Mooij; W M Bogers; H Oostermeijer; W Koornstra; P J Ten Haaft; B E Verstrepen; G Van Der Auwera; J L Heeney
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 3.  Coreceptor use in nonhuman primate models of HIV infection.

Authors:  Silvana Tasca Sina; Wuze Ren; Cecilia Cheng-Mayer
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

4.  Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.

Authors:  Mark Page; Richard Stebbings; Neil Berry; Robin Hull; Deborah Ferguson; Leanne Davis; Laura Duffy; William Elsley; Joanna Hall; Claire Ham; Mark Hassall; Bo Li; Edward T Mee; Ruby Quartey-Papafio; Nicola J Rose; Nathalie Mathy; Gerald Voss; E James Stott; Neil Almond
Journal:  Retrovirology       Date:  2012-07-16       Impact factor: 4.602

5.  Complement-mediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to SIV challenge in the macaque model for HIV/AIDS.

Authors:  Mark Page; Ruby Quartey-Papafio; Mark Robinson; Mark Hassall; Martin Cranage; James Stott; Neil Almond
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

Review 6.  The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?

Authors:  Martine Braibant; Francis Barin
Journal:  Retrovirology       Date:  2013-10-07       Impact factor: 4.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.